SynthesisFrontiers in immunology2026
SLE-associated intestinal pseudo-obstruction: a case report and analysis of 43 cases.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intestinal pseudo-obstruction (IPO) is a rare but serious gastrointestinal complication of systemic lupus erythematosus (SLE), often mimicking surgical obstruction. It may be reversible with prompt immunosuppressive therapy but is frequently misdiagnosed. Methods: We report a patient with SLE-IPO and a history of pulmonary arterial hypertension (PAH), a combination rarely described. A systematic review was conducted via PubMed and EMBASE through March 31, 2025. After deduplication and screening, 30 publications reporting 42 individual cases were included. Combined with our case, 43 cases were analyzed. Clinical characteristics, treatments, and outcomes were extracted and compared by publication date (≤2010 vs. >2010). Results: Among the 43 patients, 93.02% were female, with a median age of 32.00 years. IPO was the initial SLE presentation in 62.79%, and more than 90.00% occurred during active disease. Genitourinary involvement was present in 46.51%. All patients received corticosteroids. Cyclophosphamide was used in 37.21%, IVIG in 18.60%, MMF in 16.28%, and rituximab in 4.65%. After 2010, IVIG use increased (32.00% vs. 0.00%), along with broader use of MMF and biologics. IPO relapsed in 39.53%; mortality was low (2.33%). Our case achieved remission after escalation to intravenous methylprednisolone and IVIG, with MMF introduced only after bowel function recovered. Conclusion: SLE-IPO is a potentially reversible complication that often coexists with genitourinary dysmotility and only rarely with pulmonary hypertension. Timely diagnosis and aggressive immunosuppression are important to avoid irreversible damage or surgery. Evolving treatment strategies may be associated with improved outcomes, although causal inference is limited by case-level evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.